Viewing Study NCT06303193


Ignite Creation Date: 2025-12-25 @ 1:18 AM
Ignite Modification Date: 2025-12-25 @ 11:26 PM
Study NCT ID: NCT06303193
Status: NOT_YET_RECRUITING
Last Update Posted: 2025-12-24
First Post: 2024-03-08
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms
Sponsor: National Cancer Institute (NCI)
Organization:

Key Dates - Follows AllAPIJSON File Order

Start Date: 2025-12-29
Start Date Type: ESTIMATED
Primary Completion Date: 2030-01-01
Primary Completion Date Type: ESTIMATED
Completion Date: 2035-01-01
Completion Date Type: ESTIMATED
First Submit Date: 2024-03-08
First Submit QC Date: None
Study First Post Date: 2024-03-12
Study First Post Date Type: ACTUAL
Results First Submit Date: None
Results First Submit QC Date: None
Results First Post Date: None
Results First Post Date Type: None
Results First Post QC Date: None
Results First Post QC Date Type: None
Disp First Submit Date: None
Disp First Submit QC Date: None
Disp First Post Date: None
Disp First Post Date Type: None
Last Update Submit Date: 2025-12-23
Last Update Post Date: 2025-12-24
Last Update Post Date Type: ACTUAL